Clinical Stage IV Cutaneous Melanoma AJCC v8

specific

Stage I includes: IA: (T1a, N0, M0); IB: (T1b, N0, M0); (T2a, N0, M0). T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite me

72

Centers

204

Active Trials

Cancer Funding

Top Centers for Clinical Stage IV Cutaneous Melanoma AJCC v8(72)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
High-Volume Research Center
72.9
272.3
3
NCI Clinical
High-Volume Research Center
71.3
4
High-Volume Research Center
71.3
5
NCI Comprehensive
High-Volume Research Center
70.4
6
NCI Comprehensive
Active Research Program
68.5
7
NCI Comprehensive
Active Research Program
68.5
8
NCI Comprehensive
Active Research Program
68.5
9
Active Research Program
68.5
10
Active Research Program
68.5
11
NCI Comprehensive
Active Research Program
64.4
12
NCI Comprehensive
Active Research Program
64.4
13
NCI Comprehensive
Active Research Program
64.4
14
NCI Comprehensive
Active Research Program
64.4
15
NCI Comprehensive
Active Research Program
64.4
16
NCI Clinical
Active Research Program
64.4
17
NCI Comprehensive
Active Research Program
64.4
18
Active Research Program
64.4
19
NCI Comprehensive
Active Research Program
57.3
20
NCI Comprehensive
Active Research Program
57.3
21
NCI Comprehensive
Active Research Program
57.3
22
NCI Comprehensive
Active Research Program
57.3
23
NCI Comprehensive
Active Research Program
57.3
24
NCI Comprehensive
Active Research Program
57.3
25
NCI Comprehensive
Active Research Program
57.3
26
Active Research Program
57.3
27
NCI Comprehensive
Active Research Program
57.3
28
Active Research Program
57.3
29
NCI Clinical
Active Research Program
57.3
30
NCI Comprehensive
Active Research Program
57.3
31
NCI Comprehensive
Active Research Program
57.3
32
Active Research Program
57.3
33
Active Research Program
57.3
34
NCI Comprehensive
Active Research Program
44.4
35
NCI Comprehensive
Active Research Program
44.4
36
NCI Comprehensive
Active Research Program
44.4
37
NCI Comprehensive
Active Research Program
44.4
38
NCI Comprehensive
Active Research Program
44.4
39
NCI Comprehensive
Active Research Program
44.4
40
NCI Comprehensive
Active Research Program
44.4
41
NCI Comprehensive
Active Research Program
44.4
42
NCI Comprehensive
Active Research Program
44.4
43
NCI Comprehensive
Active Research Program
44.4
44
NCI Comprehensive
Active Research Program
44.4
45
NCI Comprehensive
Active Research Program
44.4
46
Cedars-Sinai CancerLos Angeles, CA
Active Research Program
44.4
47
NCI Comprehensive
Active Research Program
44.4
48
NCI Comprehensive
Active Research Program
44.4
49
NCI Comprehensive
Active Research Program
44.4
50
Rutgers Cancer InstituteNew Brunswick, NJ
NCI Comprehensive
Active Research Program
44.4
51
Active Research Program
44.4
52
Active Research Program
44.4
53
Active Research Program
44.4
54
Active Research Program
44.4
55
Active Research Program
44.4
56
Active Research Program
44.4
57
BC CancerVancouver, BC
Active Research Program
44.4
58
Active Research Program
44.4
59
Active Research Program
44.4
60
NCI Comprehensive
Contributing Research Center
32.3
61
NCI Comprehensive
Contributing Research Center
32.3
62
NCI Comprehensive
Contributing Research Center
32.3
63
NCI Comprehensive
Contributing Research Center
32.3
64
Contributing Research Center
32.3
65
NCI Comprehensive
Contributing Research Center
32.3
66
Fox Chase Cancer CenterPhiladelphia, PA
NCI Comprehensive
Contributing Research Center
32.3
67
Contributing Research Center
32.3
68
NCI Basic_laboratory
Contributing Research Center
32.3
69
Contributing Research Center
32.3
70
Contributing Research Center
32.3
71
Contributing Research Center
32.3
72
Contributing Research Center
32.3

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →